How is darolutamide (Nubeqa®) changing the mHSPC treatment landscape by setting a new standard of care?

Experts highlight that the ARASENS trial has revolutionized the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) by establishing triplet therapy—darolutamide, androgen deprivation therapy (ADT), and docetaxel chemotherapy—as the new standard of care. The trial demonstrated a 32.5% reduction in mortality and delayed progression to castration-resistant prostate cancer, pain, and the need for further therapies, with a favorable safety profile. This marks a significant shift from ADT monotherapy, highlighting the importance of treatment intensification. The findings emphasize improved survival and manageable toxicity, offering compelling evidence for adopting triplet therapy to enhance outcomes for men with mHSPC in clinical practice.